The Emergence of Tumor Organoid Engineering as a Powerful Tool for Drug Efficacy and Mechanism of Action Profiling
Fei Wang, Rongyun Zhou, Xinlong Dong, Jun Zhou, Hongjuan Zhang, Jessie Wang, Davy Ouyang, Xiaoxi Xu, Yujun Huang, Henry Li, Phillip Wang
Organoids are a powerful translational tool for preclinical research with several advantages over current conventional models. One of these advantages is their amenability to genetic engineering (which is not available for models such as PDX), to expand the range of models available for drug development.
We have developed over 200 PDX-derived organoid (PDXO) models which are now being engineered to express luciferase, specific tumor associated antigens (TAA), and some EGFR mutants unavailable in current preclinical model panels.
This poster details genetically engineered organoid model development methods, characterization, and initial applications.
Watch this Poster to Discover:
- How genetically engineered organoid models expand preclinical model capacity, particularly for currently unavailable EGFR mutant resources and imaging models
- How genetically engineered organoid models facilitate drug development applications including drug efficacy, in vivo bioluminescence, and immuno-oncology co-culture assays in a cost and time-effective way
- A range of engineered PDXO models, developed using HUB protocols, covering a variety of cancer types and with a range of modifications introduced